Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Recommendation of “Buy” by Brokerages

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has earned a consensus recommendation of “Buy” from the eleven analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $36.25.

AMLX has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Guggenheim increased their target price on shares of Amylyx Pharmaceuticals from $40.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. HC Wainwright boosted their price target on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wolfe Research raised shares of Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday.

Key Headlines Impacting Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Phase 3 success strengthens the product outlook. Avexitide met both the primary and secondary endpoints in the LUCIDITY trial, reducing hypoglycemic events by 55% in patients with PBH. The results provide Amylyx with a potentially important late-stage asset and support plans to submit an FDA application by the end of 2026. Reuters report on the avexitide trial
• Positive Sentiment: Analysts raised targets and ratings. Guggenheim lifted its target to $55 and assigned a “buy” rating; Robert W. Baird raised its target to $52 with an “outperform” rating; and H.C. Wainwright increased its target to $55 while maintaining a “buy” rating. Wolfe Research also upgraded the shares to “strong buy.” Benzinga analyst-rating updates
• Positive Sentiment: Investors are pricing in commercialization potential. Coverage characterized the trial as a major catalyst that could move avexitide closer to regulatory review and eventual commercialization, helping explain the unusually high trading activity and fresh stock high. Zacks analysis of Amylyx’s Phase 3 win
• Neutral Sentiment: Important milestones remain ahead. The results are topline data, so additional analysis, regulatory discussions, a formal FDA filing, and approval are still required. Commentary also cautioned that the sharp rally may have moved ahead of near-term fundamentals, increasing volatility and profit-taking risk. Invezz analysis of AMLX risks

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the transaction, the insider owned 194,090 shares in the company, valued at $3,555,728.80. The trade was a 7.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 10.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in Amylyx Pharmaceuticals during the second quarter valued at approximately $158,534,000. Jupiter Topco LLC bought a new stake in Amylyx Pharmaceuticals in the second quarter worth approximately $94,014,000. Adage Capital Partners GP L.L.C. grew its position in Amylyx Pharmaceuticals by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock worth $56,408,000 after acquiring an additional 3,102,395 shares in the last quarter. Millennium Management LLC increased its stake in shares of Amylyx Pharmaceuticals by 418.6% during the 1st quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock worth $10,910,000 after purchasing an additional 2,487,617 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Amylyx Pharmaceuticals by 76.1% during the 4th quarter. Janus Henderson Group PLC now owns 4,465,872 shares of the company’s stock worth $53,992,000 after purchasing an additional 1,929,639 shares during the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Trading Up 9.9%

Shares of NASDAQ AMLX opened at $38.60 on Thursday. Amylyx Pharmaceuticals has a one year low of $7.82 and a one year high of $39.07. The business has a 50-day moving average price of $19.38 and a two-hundred day moving average price of $16.35. The firm has a market capitalization of $4.30 billion, a PE ratio of -26.99 and a beta of -0.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). Research analysts anticipate that Amylyx Pharmaceuticals will post -1.45 EPS for the current year.

About Amylyx Pharmaceuticals

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs.